Avenue Therapeutics Future Growth
Future criteria checks 0/6
Avenue Therapeutics is forecast to grow earnings and revenue by 7.9% and 85.7% per annum respectively while EPS is expected to grow by 31.3% per annum.
Key information
7.9%
Earnings growth rate
31.3%
EPS growth rate
Pharmaceuticals earnings growth | 21.6% |
Revenue growth rate | 85.7% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 02 Apr 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -20 | -20 | N/A | 1 |
12/31/2025 | N/A | -16 | -16 | N/A | 1 |
12/31/2024 | N/A | -13 | -13 | N/A | 1 |
12/31/2023 | N/A | -10 | -12 | -9 | N/A |
9/30/2023 | N/A | -10 | -14 | -11 | N/A |
6/30/2023 | N/A | -12 | -13 | -11 | N/A |
3/31/2023 | N/A | -8 | -7 | -7 | N/A |
12/31/2022 | N/A | -4 | -8 | -8 | N/A |
9/30/2022 | N/A | -5 | -5 | -5 | N/A |
6/30/2022 | N/A | -5 | -5 | -5 | N/A |
3/31/2022 | N/A | -6 | -4 | -4 | N/A |
12/31/2021 | N/A | -4 | -4 | -4 | N/A |
9/30/2021 | N/A | -4 | -4 | -4 | N/A |
6/30/2021 | N/A | -4 | -4 | -4 | N/A |
3/31/2021 | N/A | -5 | -5 | -5 | N/A |
12/31/2020 | N/A | -5 | -5 | -5 | N/A |
9/30/2020 | N/A | -10 | -8 | -8 | N/A |
6/30/2020 | N/A | -11 | -9 | -9 | N/A |
3/31/2020 | N/A | -16 | -22 | -22 | N/A |
12/31/2019 | N/A | -26 | -26 | -26 | N/A |
9/30/2019 | N/A | -24 | -23 | -23 | N/A |
6/30/2019 | N/A | -25 | -25 | -25 | N/A |
3/31/2019 | N/A | -22 | -17 | -17 | N/A |
12/31/2018 | N/A | -22 | -18 | -18 | N/A |
9/30/2018 | N/A | -24 | -21 | -21 | N/A |
6/30/2018 | N/A | -24 | -19 | -19 | N/A |
3/31/2018 | N/A | -22 | -14 | -14 | N/A |
12/31/2017 | N/A | -12 | -7 | -7 | N/A |
9/30/2017 | N/A | -7 | N/A | -3 | N/A |
6/30/2017 | N/A | -4 | N/A | -1 | N/A |
3/31/2017 | N/A | -3 | N/A | -1 | N/A |
12/31/2016 | N/A | -3 | N/A | -2 | N/A |
9/30/2016 | N/A | -4 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 49Y0 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 49Y0 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 49Y0 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 49Y0 is forecast to have no revenue next year.
High Growth Revenue: 49Y0 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 49Y0's Return on Equity is forecast to be high in 3 years time